Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release (ESNM70) -

Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release (ESNM70)
Information type: Evidence summaries
Source: National Institute for Health
Specialities: Mental health and illness | Paediatric and neonatal medicine
Summary
This new medicine evidence summary from NICE, based on 3 short-term RCTs critically reviews and summarises the best available evidence on the safety and efficacy of guanfacine prolonged-release (Intuniv), which was launched in the UK in February 2016.
UKMi comment
The product is licensed for the treatment of attention deficit hyperactivity disorder (ADHD) in children and young people aged 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. It is not licensed for use in combination with stimulants or for adults with ADHD.
Related links: